A cluster of 24 trades filed by four lawmakers from both parties has zeroed in on companies heading into earnings season, with Boston Scientific and Home Depot standing out as the clearest focal points. Rep. Kevin Hern leads the group with five filings in BSX and four in HD, joined in the broader activity by Reps. DelBene, Miller and Blumenthal. The timing lines up directly with BSX's October 28 report and HD's November 17 release, creating a notable overlap between congressional position adjustments and upcoming catalysts.
Boston Scientific faces its first major update since a cyberattack forced the company to withdraw 2026 guidance. Consensus estimates call for EPS between $0.76 and $0.81, compared with $0.75 in the year-ago quarter, while revenue is projected near $5.18 billion against $5.07 billion previously. The stock pulled back after the cyber incident, yet analysts maintain largely positive ratings with price targets implying more than 40 percent upside from current levels around $43. Hern's repeated filings in the name, along with the bipartisan group's broader healthcare exposure that includes three trades in IQV, suggest lawmakers are positioned for commentary on recovery and revised outlook when the company reports before the market opens.
Home Depot's November print carries its own set of expectations. Wall Street anticipates EPS of roughly $3.87 to $3.96 versus $3.74 last year, with revenue seen in the $42.8 billion to $44.2 billion range. The retailer beat estimates in its most recent quarter, yet macro concerns around housing and consumer spending remain. Hern's four filings here add to the group's activity in consumer cyclical and industrial names that also include trades in ITW and ROK. Pete Sessions separately appears in three AAPL filings, extending the pattern into technology ahead of that company's report.
The data also shows Hern adding positions in OKE in energy, CDNS in software, and MRSH in financials, rounding out a diversified but earnings-timed slate. While trade direction is not uniformly disclosed in the latest batch, the concentration and volume stand out against lighter congressional weeks. With several of these companies having topped estimates recently, the filings place these portfolios squarely in front of potential volatility tied to beats, misses, or updated guidance. Market reactions will ultimately hinge on how results compare to consensus and whether forward commentary aligns with analyst models that still point to moderate growth.
This is data analysis, not financial advice.
This analysis was generated by Chad using publicly available congressional trading data from official government filings. This is not financial advice. All data is sourced from senate.gov, clerk.house.gov, and SEC EDGAR.